




2023 China Business Climate Survey Report 2023年度中国商务环境调查报告

Healthcare Products Industry Report

医疗产品行业报告







This report distills industry-specific data from the full 2023 BCS Report reflects specific industry's business climate. We hope this report is helpful for our members to measure their operations and compare business outlooks and strategies with their industry and the broader foreign business community.

We want to thank all our members who took the time to participate in the survey. Your input is greatly valued and the key to our joint success.

*All data in this report was rounded to the nearest whole number.
Therefore, some charts or graphs may not equal 100 percent.

**Some response options and categories in the BCS have changed over time to address current market realities.

- Executive Summary
- Financial Performance
- Investment Plan
- Two-Year Business Outlook
- Top three business challenges and opportunities

Healthcare Products Sector Executive Summary

- In 2022, 66% of the healthcare products sector members reported profitable financial results, 22 pp higher than the overall members.
- The sector members estimated revenue was similar to the overall members' responses, with 38% reporting an estimated revenue increase (32% for all responses)
- 47% of the sector members ranked China as their first or top three investment destinations, a similar result to the overall respondents (46%)
- One-fifth of the sector members said China's investment environment quality was deteriorating, 25 pp lower than the overall responses.
- Nearly half of the healthcare products sector members (46%) expressed the optimistic about China's economic recovery/growth, and 44% of the sector members showed pessimistic about US-China relations.
- The rising of an increasingly sizable and affluent middle class/growth in domestic consumption was the top business opportunity for healthcare product members, with 44% reporting it.





本报告从2023年度BCS报告全文中摘取了医疗服务行业的数据,以反映具体的行业商务环境情况。我们希望本报告能成为会员公司在其具体行业乃至更广泛的外资企业中,衡量业务、比较商业前景与策略的实用工具。

中国美国商会向所有参与此次调查问卷的会员机构致以诚挚的谢意。您的贡献是我们共同成功的关键。

- *本报告中的所有数据由于四舍五入至最接近的整数分图表或图像的数据 总和可能不等于总额(100%)
- **商务环境调查中的部分回答选项和类别会因反映当前市场情况而有所改 变
- 摘要
- 营收状况
- 在华投资计划
- 今后两年中国业务展望
- 在华运营前三大挑战和机遇


₹ 医疗产品概述

- 2022年,66%的医疗产品会员企业报告实现利润增长,较整体受访会员企业结果高出22个百分点。
- 该行业会员企业的预期营收和整体受访者的情况接近,其中有38%的医疗产品会员企业报告其营收增长(所有受访者中,32%的企业报告预期营收增长)
- 有47%的该行业会员企业将中国列为其首要或前三大投资目的地, 这一结果与所有受访者结果(46%)接近。
- 五分之一的该行业会员企业称中国的投资环境质量恶化,较整体会员结果低25个百分点。
- 近一半(46%)的医疗产品受访会员企业对中国的经济复苏/增长表示乐观。此外有44%的该行业会员企业对中美关系感到悲观。
- 有44%的医疗产品会员企业认为,"中产阶级规模不断扩大/国内消费增长"是该行业在华运营的最大商业机遇。



Healthcare Products Sector 2023 China Business Climate Survey Report






Healthcare Products Sector




All respondents



■ Profitable ■ Break even ■ Loss


Estimated Revenue

Healthcare Products Sector






All respondents




Investment Plan

China Investment environment quality

China ranks of near-term global investment destination











财务状况



■盈利 ■基本持平 ■亏损


医疗产品






■盈利 ■基本持平 ■亏损

66%



■上升 ■持平(± < 2%) ■下降

财务状况




■上升 ■持平(± < 2%) ■下降


投资计划

中国投资环境质量

中国在全球短期投资目的地中 的排名














Top three business challenges

Healthcare Products Sector	All Respondents
COVID-19 prevention measures 63%	Rising tension in US-China relations 66%
Rising tension in US-China relations 47%	COVID-19 prevention measures 55%
Inconsistent regulatory interpretation and unclear laws & enforcement 44%	Inconsistent regulatory interpretation and unclear laws & enforcement 32%

Top three business opportunities

Healthcare Products Sector	All Participants
Growth in domestic consumption/Rise of an increasingly sizable and affluent middle class 44%	Growth in domestic consumption/Rising of an increasingly sizable and affluent middle class 45%
Ongoing economic and market reforms 31%	Ongoing economic and market reform 36%
Expanding business to cover more of China's domestic market (e.g., entering new cities, regions) 28%	Preferential FDI policies 23%



About AmCham China Business Climate Survey Report


The China Business Climate Survey (BCS) is one of AmCham China's most important advocacy tools. It provides valuable insights to the Chinese and US governments about member companies' concerns concerning China's regulatory and policy environment and the daily business challenges they face operating in China. Furthermore, the survey provides a valuable tool for our members to measure their operations and compare business outlooks and strategies with the broader community.

Visit here for more information on the report





今后两年在华运营前景



前三大在华运营挑战

医疗服务行业	所有受访者
新冠疫情防控措施	中美关系日益紧张
63%	66%
中美关系日益紧张	新冠疫情防控措施
47%	55%
法律法规和执行不一致/不明确	法律法规和执行不一致/不明确
44%	32%

前三大在华运营机遇

医疗服务行业	所有受访者
本土消费增长/中产阶级规模不断扩大	本土消费增长/中产阶级规模不断扩大
44%	45%
持续的经济和市场改革	持续的经济和市场改革
31%	36%
扩大商业规模以覆盖更大的中国本土市场(例如进入新的城市或区域)	外商直接投资优惠政策
28%	23%



关于中国商务环境调查报告

中国商务环境调查报告(BCS)是中国美国商会最重要的政策谏言工具之一。该报告结果反映了商会会员企业对中国监管和政策环境以及在华日常运营的真实情况,为中美两国政府提供了宝贵而深入的见解。此外,报告结果也为商会会员企业以及在华外资企业在华运营、投资决策等方面提供了衡量依据。

更多详情, 请点击这里。